Human SFEMG and rodent work in JCI 2026 show sarcopenic weakness can come from postsynaptic NaV1.4 loss at the NMJ, not just wasting. Partial ClC-1 inhibition restored transmission-related force in aged rats; this is not a human drug claim.
Nature Biotechnology embeds six proteomic aging clocks in a phase 2a rentosertib IPF trial. Treated arms show concordant biological-age reductions peaking at week 4, partly dissociated from FVC gains. A dual-purpose design demo, not proof of rejuvenation.
GLP-1 receptor agonist semaglutide reverses high-fat diet-induced hippocampal microglia activation via the IGFBPL-1/PI3K/AKT pathway in mice. This article explores the molecular bridge from gut hormones to brain protection — and the gap between animal data and clinical reality.
The elderly need autologous stem cell therapy most, yet their stem cells are few and worn out. A 2026 Scientific Reports study briefly treated aged fat-derived stem cells with rapamycin plus nicotinamide, lowering p16, p21 and inflammatory cytokines while restoring differentiation by rebooting the stalled AMPK-mTOR-autophagy loop.
How to turn manual copy-pasting across CLI agent terminals into auditable mutual task assignment using dynamic discovery, capacity allocation, and file-first handoffs.
From acceleration knobs and extreme quantization to a nine-model comparison, a large-sample retest at month's end reshuffled the entire leaderboard. A record of a broken yardstick, small-sample error bars, and the current division of labor between pi and local models.